PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2241187-7 1990 However NAG index rose remarkably when CDDP was treated by CDDP. Cisplatin 39-43 N-acetyl-alpha-glucosaminidase Homo sapiens 8-11 2241187-7 1990 However NAG index rose remarkably when CDDP was treated by CDDP. Cisplatin 59-63 N-acetyl-alpha-glucosaminidase Homo sapiens 8-11 2316078-2 1990 Following prospective randomization, we examined NAG excretion during cisplatin treatment with/without nephroprotection, after intravenous urography with ionic/non-ionic contrast media, during lower/upper urinary tract infections and before/after extracorporeal shockwave lithotripsy for intrarenal calculi (first-generation equipment used). Cisplatin 70-79 N-acetyl-alpha-glucosaminidase Homo sapiens 49-52 2316078-6 1990 However, the increase in NAG excretion was less impressive during cisplatin therapy when nephroprotective amino acids were infused, and in the urography group when non-ionic contrast media were used. Cisplatin 66-75 N-acetyl-alpha-glucosaminidase Homo sapiens 25-28 6127169-4 1982 There was a significant increase in the urinary excretion of both enzymes (AAP and NAG) within 2 days of cis-platinum administration (NAG P less than 0.05 and AAP P less than 0.07). Cisplatin 105-117 N-acetyl-alpha-glucosaminidase Homo sapiens 83-86 6127169-4 1982 There was a significant increase in the urinary excretion of both enzymes (AAP and NAG) within 2 days of cis-platinum administration (NAG P less than 0.05 and AAP P less than 0.07). Cisplatin 105-117 N-acetyl-alpha-glucosaminidase Homo sapiens 134-137 11763992-11 2001 Moreover, the first course morning cisplatin and furosemide treatment was associated with less change in NAG excretion (less kidney toxicity) than the first course of evening cisplatin and furosemide treatment. Cisplatin 35-44 N-acetyl-alpha-glucosaminidase Homo sapiens 105-108 11763992-12 2001 The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course. Cisplatin 26-35 N-acetyl-alpha-glucosaminidase Homo sapiens 96-99 29445029-13 2018 The decrease in GFRcysC and increase in N-acetyl-ss-glucosaminidase (NAG) and creatinine demonstrate that these biomarkers can quantify cisplatin glomerular and proximal tubular toxicity. Cisplatin 136-145 N-acetyl-alpha-glucosaminidase Homo sapiens 40-67 29445029-13 2018 The decrease in GFRcysC and increase in N-acetyl-ss-glucosaminidase (NAG) and creatinine demonstrate that these biomarkers can quantify cisplatin glomerular and proximal tubular toxicity. Cisplatin 136-145 N-acetyl-alpha-glucosaminidase Homo sapiens 69-72